Poster Presentation COSA-IPOS Joint Scientific Meeting 2012

Review of clinical practice guidelines of chemotherapy induced oral mucositis in an Australian haematology oncology practice. (#848)

Maria A Larizza 1 , Cheree Masterson 1
  1. Alfred Health, Melbourne, VIC, Australia

Aim: Mucositis is a potentially serious side effect of chemotherapy used for severe malignancies. Concerns about potential barriers to the use of oral cryotherapy has lead to difficulties when providing patients with information. The aim was to identify those chemotherapies which benefit from the prior administration of oral cryotherapy in order to reduce the incidence of mucositis. In addition best practice guidelines will be used to implement a uniform approach to cryotherapy management targeting patient compliance.
Methods: A literature review of the following databases were comprehensively searched via Monash University Databases: EMBASE (OVID), CINAHL, Austhealth, Clinical Evidence, Cochrane Database, EBM Reviews, Current Contents, PubMed. A search from 1980 through 2012 was performed, linking the subject search headings ‘oral cryotherapy‘, ‘ice chips‘, and ‘oral mucositis‘ with each of the following headings: ‘chemotherapy‘, ‘haematology‘, ‘antineoplastic agents’, ‘guidelines’, and ‘oncology’. The search was restricted to studies of chemotherapy induced oral mucositis in which clinical practice guidelines was a major focus.
Results: The search identified a number of studies that examined oral cryotherapy on the development of chemotherapy induced oral mucositis. Studies suggest fluorouracil and melphalan are implicated in oral related complications more so than anthracycline based treatments. Practice guidelines recommend the use of cryotherapy for the following chemotherapies; fluorouracil, cycloposphamide, melphalan, methotrexate (IV), etoposide, cisplatin, mitomycin, and vinblastine. In addition patient compliance has been reported to improve with the concurrent use of sensitive toothpaste and salt and sodium bicarbonate mouthwashes. Reported limitations of oral cryotherapy include sensitive teeth, continuous infusions, cold, headaches and unwillingness to continue the cryotherapy through the entire infusion. Contraindications to the use of oral cryotherapy is existing mucositis and oxaliplatin based regimens.
Conclusion: A unit based protocol for the administration of oral cryotherapy for the purpose of reducing the incidence of mucositis was implemented as a result of this review. Furthermore, a uniform approach to cryotherapy management, targeting patient compliance, had improved confidence amongst staff.

  1. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis (p 2026-2046) Edward B. Rubenstein, Douglas E. Peterson, Mark Schubert, Dorothy Keefe, Deborah McGuire, Joel Epstein, Linda S. Elting, Philip C. Fox, Catherine Cooksley, Stephen T. Sonis Published Online: 19 Apr 2004
  2. Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011 Apr 13;(4):CD000978. Review. PubMed PMID: 21491378.
  3. Katrancı N, Ovayolu N, Ovayolu O, Sevinc A. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy – A randomized controlled trial. Eur J Oncol Nurs. 2011 Sep 10. [Epub ahead of print]PubMed PMID: 21911313.
  4. Chemotherapy: the effect of oral cryotherapy on the development of mucositis. Journal of Clinical Nursing. 2005, vol 14, issue 6
  5. Oral complications of chemotherapy & Head and neck radiation. National cancer institute. www.cancer.gov.au
  6. Boissenvain-Chan et al. 2008. “Best practise for chemotherapy induced oral mucositis.” www.nurseweb.ucsf.edu/conf/cripc/ebpabstract/boissenvain
  7. Baydar et al, 2005. “Prevention of oral mucositis due to 5FU treatment with oral cryotherapy”. Journal of the National Medical Association, Aug, page 1161-1164.